Chugai Pharmaceutical Co., Ltd. CHGCF
OTC PK
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 9.26% | 12.30% | |
| Total Other Revenue | -- | -- | 16.28% | 7.97% | |
| Total Revenue | -- | -- | 10.22% | 11.68% | |
| Cost of Revenue | -- | -- | 6.75% | 0.03% | |
| Gross Profit | -- | -- | 11.74% | 17.25% | |
| SG&A Expenses | -- | -- | 3.06% | -8.36% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | 14.58% | 90.63% | |
| Total Operating Expenses | -- | -- | 6.51% | 2.28% | |
| Operating Income | -- | -- | 14.79% | 24.39% | |
| Income Before Tax | -- | -- | 14.01% | 23.48% | |
| Income Tax Expenses | -- | -- | 20.56% | 35.83% | |
| Earnings from Continuing Operations | -- | -- | 11.54% | 19.03% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | 11.54% | 19.03% | |
| EBIT | -- | -- | 14.79% | 24.39% | |
| EBITDA | -- | -- | 18.92% | 28.56% | |
| EPS Basic | -- | -- | 11.52% | 19.00% | |
| Normalized Basic EPS | -- | -- | -46.01% | -40.20% | |
| EPS Diluted | -- | -- | 11.52% | 19.00% | |
| Normalized Diluted EPS | -- | -- | -46.01% | -40.21% | |
| Average Basic Shares Outstanding | -- | -- | 0.02% | 0.02% | |
| Average Diluted Shares Outstanding | -- | -- | 0.02% | 0.02% | |
| Dividend Per Share | -- | -- | -10.56% | -23.60% | |
| Payout Ratio | -- | -- | 0.07% | 0.01% | |